Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Research Abstract |
We investigated the possibility of microRNA-124 precursor as a useful therapeutic drug for the treatment of rheumatoid arthritis. We used the mouse collagen induced arthritis (CIA) model. We found that intravenous injection of miR-124 precursor suppressed mouse CIA demonstrated by reduction of bone destruction. Moreover, we found that miR-124 suppressed the osteoclast differentiation by directly inhibiting the expression of NFATc1 which is the critical transcription factor for osteoclast differentiation. In conclusion, we propose that miR-124a is a future candidate of therapeutic agent for human rheumatoid arthritis.
|